TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 16172184

Group type: EXPERIMENTAL
Intervention: Intravenous midazolam (1 mg) after 100 mg fluconazole
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Intravenous midazolam (1 mg) after 200 mg fluconazole
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Intravenous midazolam (1 mg) after 400 mg fluconazole
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Intravenous alfentanil (15 microg/kg) after 100 mg fluconazole
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Intravenous alfentanil (15 microg/kg) after 200 mg fluconazole
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Intravenous alfentanil (15 microg/kg) after 400 mg fluconazole
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Oral midazolam (3 mg) after 100 mg fluconazole
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Oral alfentanil (40 microg/kg) after 100 mg fluconazole
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Alfentanil miosis
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Single-point concentrations of midazolam
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Single-point concentrations of alfentanil
Number of subjects: 12
Study: 12509615

Group type: EXPERIMENTAL
Intervention: DIL with additional verbal backup
Number of subjects: 100

Group type: COMPARATOR
Intervention: DIL alone (control group)
Number of subjects: 100
Study: 10434153

Group type: EXPERIMENTAL
Intervention: Fluoxetine 20 mg/day
Number of subjects: 237

Group type: COMPARATOR
Intervention: Tianeptine 37.5 mg/day
Number of subjects: 237
Study: 8909821

Group type: EXPERIMENTAL
Intervention: Mitral valve replacement with chordal preservation
Number of subjects: 12

Group type: COMPARATOR
Intervention: Mitral valve replacement with chordal excision
Number of subjects: 12
Study: 1931347

Group type: EXPERIMENTAL
Intervention: Enalapril
Number of subjects: 17

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 17
Study: 6182817

Group type: EXPERIMENTAL
Intervention: Alloferin (alcuronium) in burned patients, initial dose 23.75 mg (0.35 mg/kg)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Alloferin (alcuronium) in control group, initial dose 15 mg (0.21 mg/kg)
Number of subjects: 12
Study: 31492121

Group type: EXPERIMENTAL
Intervention: Uitblinkers intervention (three sessions between an oral healthcare professional and parent)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Care as usual (control group)
Number of subjects: 40
Study: 29267221

Group type: EXPERIMENTAL
Intervention: 30 g whey protein (120 kcal)
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: 70 g whey protein (280 kcal)
Number of subjects: 32

Group type: COMPARATOR
Intervention: Flavored-water control drink (2 kcal)
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Whey protein ingestion
Number of subjects: 32
Study: 24304658

Group type: EXPERIMENTAL
Intervention: OPUS treatment
Number of subjects: 547

Group type: COMPARATOR
Intervention: Standard treatment
Number of subjects: 547
Study: 24359313

Group type: EXPERIMENTAL
Intervention: SPN-804 1200 mg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: SPN-804 2400 mg
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 21966947

Group type: COMPARATOR
Intervention: K301a + b (Study I)
Number of subjects: 299

Group type: COMPARATOR
Intervention: K301a (Study II)
Number of subjects: 299

Group type: COMPARATOR
Intervention: K301 (both studies)
Number of subjects: 299
Study: 19318138

Group type: EXPERIMENTAL
Intervention: Mifepristone
Number of subjects: 258

Group type: EXPERIMENTAL
Intervention: Mifepristone (plasma levels > or =1800 ng/ml)
Number of subjects: 258

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 258
Study: 17465476

Group type: EXPERIMENTAL
Intervention: Amitriptyline
Number of subjects: 181

Group type: EXPERIMENTAL
Intervention: Propranolol
Number of subjects: 181
Study: 15162890

Group type: EXPERIMENTAL
Intervention: Intravenous tobramycin every 24 hours (10 mg/kg/dose for patients aged 6 months to < 9 years, 8 mg/kg/dose for 9 to < 12 years, 6 mg/kg/dose for ≥ 12 years)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Intravenous tobramycin every 8 hours (2.5 mg/kg/dose)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Intravenous tobramycin every 24 hours
Number of subjects: 60
Study: 16085504

Group type: EXPERIMENTAL
Intervention: Active nicotine patch
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo patch
Number of subjects: 0
Study: 10575068

Group type: EXPERIMENTAL
Intervention: Sorbothane insole
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Cambion insole
Number of subjects: 11

Group type: COMPARATOR
Intervention: Control (no insoles)
Number of subjects: 11
Study: 8762219

Group type: EXPERIMENTAL
Intervention: Nicardipine 50 mg slow release form (n = 57)
Number of subjects: 111

Group type: COMPARATOR
Intervention: Captopril 25 mg twice daily (n = 54)
Number of subjects: 111
Study: 1756043

Group type: EXPERIMENTAL
Intervention: Cefazolin (1 g single preoperative dose)
Number of subjects: 127

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 127
Study: 6124442

Group type: EXPERIMENTAL
Intervention: Propranolol (5 mg i.v.)
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Labetalol (20 mg i.v.)
Number of subjects: 14

Group type: COMPARATOR
Intervention: Practolol (10 mg i.v.)
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Labetalol (200 mg x 2, oral)
Number of subjects: 14

Group type: COMPARATOR
Intervention: Placebo (oral)
Number of subjects: 14
Study: 30807456

Group type: EXPERIMENTAL
Intervention: Transanal hemorrhoidal dearterialization with mucopexy
Number of subjects: 80

Group type: COMPARATOR
Intervention: Vessel-sealing device hemorrhoidectomy
Number of subjects: 80
Study: 29561483

Group type: EXPERIMENTAL
Intervention: Mixed conventional/piezosurgery preparation
Number of subjects: 26

Group type: COMPARATOR
Intervention: Conventional preparation with drills
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 26
Study: 27001425

Group type: EXPERIMENTAL
Intervention: Propofol
Number of subjects: 40

Group type: COMPARATOR
Intervention: Sevoflurane
Number of subjects: 40
Study: 25011352

Group type: EXPERIMENTAL
Intervention: HDM SLIT-tablet (maximum dose 32 DU in adults, 12 DU in children), administered once daily for 28 days
Number of subjects: 143

Group type: COMPARATOR
Intervention: Placebo, administered once daily for 28 days
Number of subjects: 143

Group type: EXPERIMENTAL
Intervention: HDM SLIT-tablet (maximum dose 12 DU in children), administered once daily for 28 days
Number of subjects: 143
Study: 22739396

Group type: EXPERIMENTAL
Intervention: Rosuvastatin 10 mg/day
Number of subjects: 76

Group type: COMPARATOR
Intervention: Pravastatin 40 mg/day
Number of subjects: 76
Study: 20584227

Group type: EXPERIMENTAL
Intervention: Almotriptan 12.5 mg administered within 1 h of pain onset and when pain was mild (early + mild intervention group)
Number of subjects: 501
Study: 16950591

Group type: EXPERIMENTAL
Intervention: Problem solving training combined with education on DASH diet
Number of subjects: 78

Group type: COMPARATOR
Intervention: Education on DASH diet alone
Number of subjects: 78
Study: 15616079

Group type: EXPERIMENTAL
Intervention: 0.1 mg/kg IV morphine
Number of subjects: 66

Group type: EXPERIMENTAL
Intervention: 20 mL of 0.5% bupivacaine infiltrated subcutaneously
Number of subjects: 66

Group type: EXPERIMENTAL
Intervention: Inhaled 50% nitrous oxide in oxygen (Entonox) via a demand valve
Number of subjects: 66
Study: 11851182

Group type: EXPERIMENTAL
Intervention: Intracutaneous injections of botulinum toxin (Botox) 2.5 U/0.1 ml, injected at 0.5 U/cm2 with 1 cm distance between injection points.
Number of subjects: 4
Study: 10468682

Group type: EXPERIMENTAL
Intervention: Famotidine 80 mg b.d., clarithromycin 250 mg b.d. and metronidazole 500 mg b.d. (FCM group; n = 60)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Omeprazole 20 mg o.d., clarithromycin 250 mg b.d. and metronidazole 500 mg b.d. (OCM group; n = 60)
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Famotidine 80 mg b.d., clarithromycin 250 mg b.d. and metronidazole 500 mg b.d. (FCM group; n = 52)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Omeprazole 20 mg o.d., clarithromycin 250 mg b.d. and metronidazole 500 mg b.d. (OCM group; n = 57)
Number of subjects: 120
Study: 8589025

Group type: EXPERIMENTAL
Intervention: Cisplatin 8 mg/m2 on days 1-2, 8-9, 15-16, 22-23 and 5-fluorouracil 300 mg/m2 on days 3-7, 10-14, 17-21, 24-28 (35-day courses)
Number of subjects: 44
Study: 31259883

Group type: EXPERIMENTAL
Intervention: Genotype-guided warfarin dosing
Number of subjects: 2264

Group type: COMPARATOR
Intervention: Traditional clinically guided warfarin dosing (Control)
Number of subjects: 2264
Study: 29164409

Group type: EXPERIMENTAL
Intervention: 12-week program of behavioral activation emphasizing safe-sun exposure (N=10)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Waiting list control group (N=10)
Number of subjects: 20
Study: 26754176

Group type: EXPERIMENTAL
Intervention: Ceftriaxone administered at home
Number of subjects: 188

Group type: COMPARATOR
Intervention: Flucloxacillin administered in hospital
Number of subjects: 188
Study: 24961194

Group type: EXPERIMENTAL
Intervention: SCS-ACTIVE (delivered at 90% paraesthesia threshold)
Number of subjects: 9

Group type: COMPARATOR
Intervention: SCS-INACTIVE
Number of subjects: 9
Study: 22855599

Group type: EXPERIMENTAL
Intervention: CD25(POS)
Number of subjects: 657
Study: 19470925

Group type: EXPERIMENTAL
Intervention: Paclitaxel (225 mg/m²) plus Carboplatin (AUC 6)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Genotypic variants analysis
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: CYP3A4*1B
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: ERCC2 K751Q
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: ABCB1 3425C‐‐>T
Number of subjects: 0
Study: 17845835

Group type: EXPERIMENTAL
Intervention: Spinal cord stimulation plus conventional medical management (SCS group)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Conventional medical management alone (CMM group)
Number of subjects: 100
Study: 14754579

Group type: EXPERIMENTAL
Intervention: Succimer
Number of subjects: 780

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 780
Study: 11351919

Group type: EXPERIMENTAL
Intervention: Pharmaceutical care program implemented at CVS pharmacies
Number of subjects: 1100
Study: 9783644

Group type: EXPERIMENTAL
Intervention: HMG reductase inhibitors
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: High-dose reductase inhibitors
Number of subjects: 0

Group type: COMPARATOR
Intervention: Not available
Number of subjects: 0
Study: 7846939

Group type: EXPERIMENTAL
Intervention: Sotalol
Number of subjects: 82

Group type: COMPARATOR
Intervention: Quinidine/Verapamil
Number of subjects: 82
Study: 3048574

Group type: EXPERIMENTAL
Intervention: Busulfan maintenance plus pulsed doses of cytarabine and lomustine
Number of subjects: 0

Group type: COMPARATOR
Intervention: Busulfan maintenance
Number of subjects: 0
Study: 30086252

Group type: EXPERIMENTAL
Intervention: Negative pressure wound therapy (NPWT)
Number of subjects: 110

Group type: COMPARATOR
Intervention: Standard dressing (povidone-iodine gauze and patch)
Number of subjects: 110
Study: 27940458

Group type: EXPERIMENTAL
Intervention: T50 test (blood calcification propensity)
Number of subjects: 2785
Study: 25373796

Group type: EXPERIMENTAL
Intervention: SIRT
Number of subjects: 24

Group type: COMPARATOR
Intervention: DEB-TACE
Number of subjects: 24
Study: 24242776

Group type: EXPERIMENTAL
Intervention: Prophylactic transpapillary pancreatic stenting (PTPS)
Number of subjects: 200

Group type: COMPARATOR
Intervention: Control group (no PTPS)
Number of subjects: 200
Study: 20454974

Group type: EXPERIMENTAL
Intervention: 10 MU IFN α2b s.c. 5 ×/week, followed by either 5 MU or 10 MU IFN α2b s.c. 3 ×/week for a total of 2 years
Number of subjects: 66
Study: 18410952

Group type: EXPERIMENTAL
Intervention: Genistein (54 mg/day)
Number of subjects: 104

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 104
Study: 17274494

Group type: EXPERIMENTAL
Intervention: Monetary incentives
Number of subjects: 4

Group type: COMPARATOR
Intervention: Comparative intervention or control
Number of subjects: 4
Study: 12757998

Group type: EXPERIMENTAL
Intervention: Enrolled in CAST
Number of subjects: 3163

Group type: COMPARATOR
Intervention: Nonenrolled in CAST
Number of subjects: 3163

Group type: EXPERIMENTAL
Intervention: Under study management in CAST
Number of subjects: 3163

Group type: EXPERIMENTAL
Intervention: Enrolled in AVID
Number of subjects: 3163

Group type: COMPARATOR
Intervention: Nonenrolled in AVID
Number of subjects: 3163
Study: 10763397

Group type: EXPERIMENTAL
Intervention: 900-mL 75-g OGTT
Number of subjects: 10

Group type: COMPARATOR
Intervention: 600-mL 75-g OGTT
Number of subjects: 10

Group type: COMPARATOR
Intervention: 300-mL 75-g OGTT
Number of subjects: 10
Study: 9029414

Group type: EXPERIMENTAL
Intervention: Intravenous forskolin (75 minute infusion)
Number of subjects: 9
Study: 1386905

Group type: EXPERIMENTAL
Intervention: Recombinant vaccine
Number of subjects: 96

Group type: COMPARATOR
Intervention: Plasma-derived vaccine
Number of subjects: 96
Study: 6649055

Group type: EXPERIMENTAL
Intervention: Timolol plus hydrochlorothiazide plus amiloride
Number of subjects: 32

Group type: COMPARATOR
Intervention: Methyldopa
Number of subjects: 32
Study: 31515553

Group type: EXPERIMENTAL
Intervention: Meat intake
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Sugar-sweetened beverage (SSB) intake
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Fish intake
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: RBCs and hair
Number of subjects: 32
Study: 29880546

Group type: EXPERIMENTAL
Intervention: Repetitive CD34+ cell therapy (group A)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Single-dose CD34+ cell therapy (group B)
Number of subjects: 60
Study: 26834067

Group type: EXPERIMENTAL
Intervention: Embolization with microspheres alone (Bead Block [BB])
Number of subjects: 101

Group type: COMPARATOR
Intervention: Embolization with doxorubicin-eluting microspheres (LC Bead [LCB])
Number of subjects: 101

Group type: EXPERIMENTAL
Intervention: Embolization with microspheres alone (BB)
Number of subjects: 101

Group type: COMPARATOR
Intervention: Embolization with doxorubicin-eluting microspheres (LCB)
Number of subjects: 101
Study: 25363186

Group type: EXPERIMENTAL
Intervention: omega-3 (1000 mg/day)
Number of subjects: 60

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 60
Study: 22464659

Group type: EXPERIMENTAL
Intervention: Supplemental video module (study group)
Number of subjects: 300

Group type: COMPARATOR
Intervention: Routine preoperative discussion (control group)
Number of subjects: 300
Study: 20435865

Group type: EXPERIMENTAL
Intervention: Altitude exposure at 1860 m and 2590 m (CPAP discontinued)
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: Altitude exposure at 2590 m (CPAP discontinued)
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: Altitude exposure (CPAP discontinued)
Number of subjects: 34
Study: 17655969

Group type: EXPERIMENTAL
Intervention: Adapalene 0.1% - Benzoyl Peroxide 2.5% (adapalene-BPO)
Number of subjects: 517

Group type: COMPARATOR
Intervention: Adapalene 0.1%
Number of subjects: 517

Group type: COMPARATOR
Intervention: Benzoyl Peroxide 2.5%
Number of subjects: 517

Group type: COMPARATOR
Intervention: Vehicle
Number of subjects: 517
Study: 15686271

Group type: EXPERIMENTAL
Intervention: Hyperbaric Oxygen Therapy (HBO2), 120 treatments in blocks of 80 and 40 with a five-month break
Number of subjects: 5

Group type: COMPARATOR
Intervention: Healthy controls (normal controls)
Number of subjects: 5

Group type: COMPARATOR
Intervention: Head injured controls (HIC)
Number of subjects: 5
Study: 11431192

Group type: EXPERIMENTAL
Intervention: Intraperitoneal cefepime, 1 g once daily (group A)
Number of subjects: 81

Group type: COMPARATOR
Intervention: Intravenous vancomycin and netilmicin at conventional doses (group B)
Number of subjects: 81
Study: 9505075

Group type: EXPERIMENTAL
Intervention: PTCA
Number of subjects: 1829

Group type: COMPARATOR
Intervention: CABG
Number of subjects: 1829
Study: 8279402

Group type: EXPERIMENTAL
Intervention: High-protein diet (15% of total energy as protein)
Number of subjects: 35

Group type: COMPARATOR
Intervention: Standard-protein diet (7.5% of energy as protein)
Number of subjects: 35
Study: 2929486

Group type: EXPERIMENTAL
Intervention: Breakfast
Number of subjects: 0

Group type: COMPARATOR
Intervention: Omitting breakfast
Number of subjects: 0
Study: 785587

Group type: EXPERIMENTAL
Intervention: pepstatin
Number of subjects: 9
Study: 29720238

Group type: EXPERIMENTAL
Intervention: 48 hours of postoperative intravenously administered (IV) antibiotics
Number of subjects: 1066

Group type: COMPARATOR
Intervention: 5 days of postoperative IV antibiotics
Number of subjects: 1066

Group type: EXPERIMENTAL
Intervention: 48 hours of postoperative IV antibiotics
Number of subjects: 1066
Study: 27513155

Group type: EXPERIMENTAL
Intervention: Axillary Lymph Node Dissection (ALND)
Number of subjects: 891

Group type: COMPARATOR
Intervention: Sentinel Lymph Node Dissection (SLND) alone
Number of subjects: 891

Group type: EXPERIMENTAL
Intervention: Both groups (ALND and SLND)
Number of subjects: 891
Study: 25029914

Group type: EXPERIMENTAL
Intervention: Shock-absorbing insoles (SAIs)
Number of subjects: 75

Group type: COMPARATOR
Intervention: Usual insoles (Control)
Number of subjects: 75
Study: 23043090

Group type: EXPERIMENTAL
Intervention: Cognitive behavioural therapy
Number of subjects: 5030

Group type: COMPARATOR
Intervention: Attention control
Number of subjects: 5030

Group type: COMPARATOR
Intervention: Usual school provision
Number of subjects: 5030
Study: 20383111

Group type: EXPERIMENTAL
Intervention: Filling with bone substitute and calcium sulphate post extraction
Number of subjects: 22

Group type: COMPARATOR
Intervention: No filling with any type of material post extraction (control group)
Number of subjects: 22
Study: 18608311

Group type: EXPERIMENTAL
Intervention: Cognitive behavioural group therapy for a 10-week period with relevant homework activities
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: Patient self-report of homework compliance
Number of subjects: 46

Group type: COMPARATOR
Intervention: Independent ratings of homework compliance
Number of subjects: 46
Study: 15911196

Group type: EXPERIMENTAL
Intervention: Multimedia with printed nursing guides
Number of subjects: 0

Group type: COMPARATOR
Intervention: Routine care (Control)
Number of subjects: 0
Study: 12717068

Group type: EXPERIMENTAL
Intervention: Subdermal injection of both blue dye and radiotracer (Group A)
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Periareolar injection of blue dye and subdermal injection of radiotracer (Group B)
Number of subjects: 150
Study: 11048604

Group type: EXPERIMENTAL
Intervention: Enoxaparin
Number of subjects: 0
Study: 8868037

Group type: EXPERIMENTAL
Intervention: Weight loss group (dietary modification and exercise)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 0
Study: 1380024

Group type: EXPERIMENTAL
Intervention: Paracentesis with Dextran 70 (6 g for each 1000 ml of ascites removed)
Number of subjects: 41

Group type: COMPARATOR
Intervention: Paracentesis with albumin (6 g for each 1000 ml of ascites)
Number of subjects: 41
Study: 6436832

Group type: EXPERIMENTAL
Intervention: 75 mg sulfinpyrazone and 75 mg dipyridamole
Number of subjects: 76

Group type: EXPERIMENTAL
Intervention: 150 mg ASA and 75 mg dipyridamole
Number of subjects: 76

Group type: EXPERIMENTAL
Intervention: 330 mg ASA and 75 mg dipyridamole
Number of subjects: 76

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 76
Study: 31619187

Group type: EXPERIMENTAL
Intervention: Daprodustat 10 mg TIW
Number of subjects: 103

Group type: EXPERIMENTAL
Intervention: Daprodustat 15 mg TIW
Number of subjects: 103

Group type: EXPERIMENTAL
Intervention: Daprodustat 25 mg TIW
Number of subjects: 103

Group type: EXPERIMENTAL
Intervention: Daprodustat 30 mg TIW
Number of subjects: 103

Group type: COMPARATOR
Intervention: Placebo TIW
Number of subjects: 103
Study: 30135258

Group type: EXPERIMENTAL
Intervention: Cerebello-spinal tDCS (5 d/wk for 2 weeks)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Sham stimulation
Number of subjects: 20
Study: 26787085

Group type: EXPERIMENTAL
Intervention: Immediate recall group (immediate-RG; n = 10)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Delayed recall group (delayed-RG; n = 8)
Number of subjects: 18
Study: 24824481

Group type: EXPERIMENTAL
Intervention: Cognitive Behavioural Therapy (CBT) as an adjunct to usual care (12-18 sessions)
Number of subjects: 469

Group type: COMPARATOR
Intervention: Usual care alone
Number of subjects: 469

Group type: EXPERIMENTAL
Intervention: Cognitive Behavioural Therapy (CBT) as an adjunct to usual care
Number of subjects: 469
Study: 22178576

Group type: EXPERIMENTAL
Intervention: Prasugrel 10/2.5mg
Number of subjects: 84

Group type: EXPERIMENTAL
Intervention: Prasugrel 15/3.75mg
Number of subjects: 84

Group type: EXPERIMENTAL
Intervention: Prasugrel 20/5mg
Number of subjects: 84

Group type: COMPARATOR
Intervention: Clopidogrel 300/75mg
Number of subjects: 84
Study: 20022344

Group type: EXPERIMENTAL
Intervention: Cortisol (160 mg/d for 4 days)
Number of subjects: 21

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 21
Study: 17643693

Group type: EXPERIMENTAL
Intervention: 133-cm-long, small-caliber, prototype videoendoscope
Number of subjects: 157

Group type: COMPARATOR
Intervention: 92-cm-long, small-caliber, fiberoptic endoscope
Number of subjects: 157
Study: 16226134

Group type: EXPERIMENTAL
Intervention: Prednisolone 50 mg twice a day
Number of subjects: 9
Study: 12390100

Group type: EXPERIMENTAL
Intervention: Colostrum enema (100 mL of 10% solution)
Number of subjects: 14

Group type: COMPARATOR
Intervention: Placebo (albumin solution)
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Colostrum enema
Number of subjects: 14

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 14
Study: 10458123

Group type: EXPERIMENTAL
Intervention: Topical 0.2 percent nifedipine gel every 12 hours for three weeks
Number of subjects: 283

Group type: COMPARATOR
Intervention: Topical 1 percent lidocaine and 1 percent hydrocortisone acetate gel
Number of subjects: 283
Study: 9282631

Group type: EXPERIMENTAL
Intervention: Intravenous administration of chloroquine (800 mg in three hours infusion)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Control group (not specified treatment)
Number of subjects: 10
Study: 2882775

Group type: EXPERIMENTAL
Intervention: Exercise (graduated treadmill exercise to heart rates of 160 to 170 beats min‐1)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Isoprenaline infusion (to heart rates of 100 to 110 beats min‐1)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Beta‐adrenoceptor blockers
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Calcium channel antagonists
Number of subjects: 12

Group type: COMPARATOR
Intervention: Control and placebo observations
Number of subjects: 12